Search
All Clinical Trials
A listing of 23115 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
7393 - 7404 of 23115
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Featured Offer
Ketamine Therapy—At Home, Clinician-Guided (Innerwell)
If you’re exploring options besides a clinical trial, Innerwell provides at-home ketamine therapy with medical oversight and structured support. Ketamine-assisted treatment may help “reset” rigid stress and mood patterns, and some people feel relief within a few sessions. Your care team works with you to tailor treatment and track progress every step of the way. Proven effective for Anxiety, PTSD, Depression, Addiction, and other disease areas.
Conditions:
Anxiety
Anxiety Disorders
Generalized Anxiety Disorder
Depression
Depression
Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
Recruiting
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical study in women aged 35 to 42 years. This study will investigate the safety and efficacy of Progesterone-IBSA to support euploid embryo blastocyst implantation and early pregnancy after frozen embryo transfer (FET) in a modified natural cycle as a treatment for infertile women. Subjects will be randomized to receive either active Progesterone-IBSA or Crinone 8% for luteal and early pregnancy... Read More
Gender:
FEMALE
Ages:
Between 35 years and 42 years
Trial Updated:
06/23/2025
Locations: The Fertility Treatment Center, LLC, Tempe, Arizona +21 locations
Conditions: Infertility
Evaluate the Continued Safety and Performance of the Foot and Ankle Products
Recruiting
The objective of the registry is to evaluate the continued safety and performance of Arthrex foot and ankle products, including the ProStop® implant for hyperpronated foot; Bio-Compression Screw for reconstruction surgeries of the foot; TRIM-IT Drill Pin® system and/or TRIM-IT Spin Pin™ system for fixation of fractures and fusion (bunionectomy osteotomies) of the foot/ankle; Headless Compression Screws and Compression FT Screws for fixation of small bone fragments of the foot/ankle; DynaNite® ni... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/23/2025
Locations: UC Davis Medical Center, Sacramento, California +5 locations
Conditions: Hyperpronated Foot, Reconstruction Surgeries of the Foot, Fixation of Fractures and Fusion (Bunionectomy Osteotomies) of the Foot/Ankle, Fixation of Small Bone Fragments of the Foot/Ankle, Lisfranc Arthrodesis, Mono or Bi-cortical Osteotomies in the Forefoot, First Metatarsophalangeal Arthrodesis, Akin Osteotomy, Midfoot and Hindfoot Arthrodeses or Osteotomies, Fixation of Osteotomies for Hallux Valgus Treatment (Scarf and Chevron), Arthrodesis of the Metatarsocuneiform Joint to Reposition and Stabilize Metatarsus Primus Varus, Osteotomy Fixation of Hallux Valgus Repair (Such as Scarf and Chevron Etc.), Medial Ankle Stabilization, Tibiotalocalcaneal Arthrodesis
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Recruiting
A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of California, Irvine, Orange, California +50 locations
Conditions: Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Recruiting
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site
Registry of Arthrex Hand and Wrist Products
Recruiting
A Multi-Center, Prospective Registry to Evaluate the Continued Safety and Effectiveness of Hand and Wrist Products
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: MORE Foundation, Phoenix, Arizona +4 locations
Conditions: Ulnar/Radial Collateral Ligament Reconstruction, Ligament Repair or Reconstruction, Small Bone Fragments and Arthrodesis, Scapholunate Ligament Reconstruction, Carpal Fusion (Arthrodesis) of the Hand, Digital Tendon Transfers, Carpometacarpal Joint Arthroplasty, Arthrodesis, Digital Tendon Transfer, Distal Radius Fracture Fixation
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Recruiting
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: St Luke's Hospital, Kansas City, Kansas +13 locations
Conditions: Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)
Recruiting
The goal of this observational study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test
Gender:
FEMALE
Ages:
Between 14 years and 50 years
Trial Updated:
06/23/2025
Locations: New Horizons Clinical Trials, Chandler, Arizona +9 locations
Conditions: Endometriosis
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Recruiting
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Northwestern University Robert H Lurie Medical Research, Chicago, Illinois +3 locations
Conditions: Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
Recruiting
The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/23/2025
Locations: Curevo Investigational Site, Tempe, Arizona +12 locations
Conditions: Herpes Zoster, Shingles
A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Recruiting
This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: D3 Bio Investigative Site, Orange, California +46 locations
Conditions: KRAS P.G12C
Medication Adherence in Patients With Sarcoidosis
Recruiting
The goal of the study is to look at the relationship between how individuals with Sarcoidosis take the sarcoidosis medicines and how it affects the disease, to evaluate any factors that may make individuals not want to take the medicines, and to develop and refine ways to help support individuals with Sarcoidosis especially when it comes to the medicines. The overall hypothesis is higher medication adherence will be associated with better clinical outcomes in sarcoidosis. The investigators will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Johns Hopkins Bayview Asthma and Allergy Center, Baltimore, Maryland +1 locations
Conditions: Medication Adherence, Sarcoidosis
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
Recruiting
This phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab \[DA-EPOCH+/-R\]) with the addition of targeted therapy (tafasitamab) for the treatment of patients with newly diagnosed Philadelphia chromosome negative (Ph-) B acute lymphoblastic leukemia (B-ALL). Chemotherapy drugs, such as those in EPOCH+/-R, work in different ways to stop the growth of cancer cells, either by killing the cel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
7393 - 7404 of 23115
